Literature DB >> 28903888

Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta.

Hacer Uyanıkoğlu1, Adnan İncebıyık1, Ahmet B Turp1, Güler Çakmak1, Sibel Sak1, Neşe G Hilali1.   

Abstract

BACKGROUND: Placenta percreta is the morbidly adherent form of all the placental invasion abnormalities. The pathology that underlies placenta percreta is poorly understood. AIMS: To compare the levels of circulating vascular endothelial growth factor, placental growth factor and soluble fms-like tyrosine kinase 1 in pregnant women with placenta percreta to a control group. STUDY
DESIGN: Case-control study.
METHODS: Twenty-two women who underwent caesarean section due to placenta percreta and 22 women who underwent caesarean section for other obstetric reasons were included in this study. The diagnosis of placenta percreta was defined as extreme trophoblastic invasion involving serosa of the uterus. Venous blood samples were collected for biochemical comparison of circulating vascular endothelial growth factor, placental growth factor and soluble fms-like tyrosine kinase 1 from all pregnant women.
RESULTS: Women with placenta percreta were significantly older, had higher gravidity, received more frequent antenatal steroids and blood transfusions and delivered at an earlier gestational age when compared to the control group. In women with placenta percreta, preoperative circulating levels of vascular endothelial growth factor, placental growth factor and soluble fms-like tyrosine kinase 1 were lower than the controls (p<0.001, p<0.001 and p<0.05, respectively). While the postoperative levels of vascular endothelial growth factorand soluble fms-like tyrosine kinase 1 levels were higher in placenta percreta (p=0.001 and p<0.001, respectively), placental growth factor levels were similar in both groups.
CONCLUSION: The findings of this study suggest that a decrease in vascular endothelial growth factor, placental growth factor and soluble fms-like tyrosine kinase 1 levels may be related to placenta percreta etiopathogenesis.

Entities:  

Keywords:  Placenta percreta; fms-Like tyrosine kinase 1 vascular endothelial growth factor.; placental growth factor

Mesh:

Substances:

Year:  2017        PMID: 28903888      PMCID: PMC5820448          DOI: 10.4274/balkanmedj.2016.1890

Source DB:  PubMed          Journal:  Balkan Med J        ISSN: 2146-3123            Impact factor:   2.021


  19 in total

Review 1.  Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review.

Authors:  A Ahmed; C Dunk; S Ahmad; A Khaliq
Journal:  Placenta       Date:  2000 Mar-Apr       Impact factor: 3.481

Review 2.  Soluble flt-1 and the angiopoietins in the development and regulation of placental vasculature.

Authors:  D Stephen Charnock-Jones
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

3.  Accuracy of ultrasound in antenatal diagnosis of placental attachment disorders.

Authors:  E Pilloni; M G Alemanno; P Gaglioti; A Sciarrone; A Garofalo; M Biolcati; G Botta; E Viora; T Todros
Journal:  Ultrasound Obstet Gynecol       Date:  2016-02-09       Impact factor: 7.299

Review 4.  [Potential role of the angiogenic factor "EG-VEGF" in gestational trophoblastic diseases].

Authors:  H Boufettal; J-J Feige; M Benharouga; T Aboussaouira; S Nadifi; S Mahdaoui; N Samouh; N Alfaidy
Journal:  Pathol Biol (Paris)       Date:  2013-05-04

5.  Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies.

Authors:  S Helske; P Vuorela; O Carpén; C Hornig; H Weich; E Halmesmäki
Journal:  Mol Hum Reprod       Date:  2001-02       Impact factor: 4.025

6.  Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.

Authors:  Mark J Wehrum; Irina A Buhimschi; Carolyn Salafia; Stephen Thung; Mert O Bahtiyar; Erica F Werner; Katherine H Campbell; Christine Laky; Anna K Sfakianaki; Guomao Zhao; Edmund F Funai; Catalin S Buhimschi
Journal:  Am J Obstet Gynecol       Date:  2011-02-12       Impact factor: 8.661

7.  Serum angiogenic profile in abnormal placentation.

Authors:  Ebru Biberoglu; Ayse Kirbas; Korkut Daglar; Kutay Biberoglu; Hakan Timur; Canan Demirtas; Erdem Karabulut; Nuri Danisman
Journal:  J Matern Fetal Neonatal Med       Date:  2016-02-10

8.  [Maternal serum concentration of angiogenic factors: PIGF, VEGF and VEGFR-1 and placental volume in pregnancies complicated by intrauterine growth restriction].

Authors:  Anna Semczuk-Sikora; Arkadiusz Krzyzanowski; Norbert Stachowicz; Jacek Robak; Janusz Kraczkowski; Maciej Kwiatek; Marian Semczuk
Journal:  Ginekol Pol       Date:  2007-10       Impact factor: 1.232

Review 9.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

10.  Circulating angiogenic factors and the risk of preeclampsia.

Authors:  Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

View more
  3 in total

1.  Soluble FMS-Like Tyrosine Kinase-1: Role in placenta accreta spectrum disorder.

Authors:  Sarma Lumbanraja; M Rizki Yaznil; Andre M Siahaan; Bancin Berry Eka Parda
Journal:  F1000Res       Date:  2021-07-21

2.  Development and validation of a four-microRNA signature for placenta accreta spectrum: an integrated competing endogenous RNA network analysis.

Authors:  Tian Yang; Na Li; Rui Hou; Chong Qiao; Caixia Liu
Journal:  Ann Transl Med       Date:  2020-08

3.  Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study.

Authors:  Alexander Schwickert; Frédéric Chantraine; Loreen Ehrlich; Wolfgang Henrich; Mustafa Zelal Muallem; Andreas Nonnenmacher; Philippe Petit; Katharina Weizsäcker; Thorsten Braun
Journal:  Reprod Sci       Date:  2020-10-06       Impact factor: 3.060

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.